DK2254591T3 - Inhibering eller behandling af gastrointestinal biofilm - Google Patents

Inhibering eller behandling af gastrointestinal biofilm

Info

Publication number
DK2254591T3
DK2254591T3 DK09709038.5T DK09709038T DK2254591T3 DK 2254591 T3 DK2254591 T3 DK 2254591T3 DK 09709038 T DK09709038 T DK 09709038T DK 2254591 T3 DK2254591 T3 DK 2254591T3
Authority
DK
Denmark
Prior art keywords
inhibition
treatment
gastrointestinal biofilm
biofilm
gastrointestinal
Prior art date
Application number
DK09709038.5T
Other languages
English (en)
Inventor
Stephen F Olmstead
Original Assignee
Prothera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothera Inc filed Critical Prothera Inc
Application granted granted Critical
Publication of DK2254591T3 publication Critical patent/DK2254591T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK09709038.5T 2008-02-08 2009-02-09 Inhibering eller behandling af gastrointestinal biofilm DK2254591T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6518608P 2008-02-08 2008-02-08
PCT/US2009/033599 WO2009100456A2 (en) 2008-02-08 2009-02-09 Inhibition and treatment of gastrointestinal biofilms

Publications (1)

Publication Number Publication Date
DK2254591T3 true DK2254591T3 (da) 2017-11-06

Family

ID=40939056

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09709038.5T DK2254591T3 (da) 2008-02-08 2009-02-09 Inhibering eller behandling af gastrointestinal biofilm

Country Status (10)

Country Link
US (3) US20090202516A1 (da)
EP (1) EP2254591B1 (da)
JP (2) JP6047273B2 (da)
CA (1) CA2715266A1 (da)
DK (1) DK2254591T3 (da)
ES (1) ES2645062T3 (da)
NO (1) NO2254591T3 (da)
PL (1) PL2254591T3 (da)
PT (1) PT2254591T (da)
WO (1) WO2009100456A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513305B2 (en) 2007-05-14 2013-08-20 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
CA2720301C (en) * 2008-04-03 2017-11-07 Kane Biotech Inc. Dispersinb tm, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof
US20110091606A1 (en) * 2009-09-23 2011-04-21 Todd Ehrlich Dietary Supplements in Beverages or Other Forms, and Methods of Use and Production
EP2504025A4 (en) * 2009-11-23 2013-05-01 Stephen F Olmstead COMPOSITIONS AND METHODS USING SERRATIA PEPTIDASE FOR INHIBITING AND TREATING BIOFILMS ASSOCIATED WITH PARTICULAR SUFFERING
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US20120070423A1 (en) * 2010-09-21 2012-03-22 Puneet Nanda Oral composition and method of forming and using same
WO2012106264A2 (en) * 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
US9504739B2 (en) 2011-03-01 2016-11-29 Quorum Innovations, Llc Method of identifying a biologically-active composition from a biofilm
US20120315260A1 (en) * 2011-06-13 2012-12-13 Svetlana A. Ivanova Compositions and Methods to Prevent and Treat Biofilms
US10420822B2 (en) 2011-06-13 2019-09-24 Ziolase, Llc Compositions and methods to prevent and treat biofilms
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
WO2014130007A1 (en) * 2013-02-19 2014-08-28 Deerland Enzymes, Inc. Proteolytic compositions for rapidly and extensively degrading protein supplements
US20190192639A1 (en) * 2016-06-08 2019-06-27 Onelife S.A. Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
CA3055915A1 (en) * 2017-03-10 2018-09-13 Biohm Health Llc Compositions and methods for disrupting biofilms of pathogenic bacteria or fungi
CN108359696A (zh) * 2018-02-28 2018-08-03 苏州昆蓝生物科技有限公司 一种低聚木糖的制备方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN118252181A (zh) * 2024-05-30 2024-06-28 中国农业科学院北京畜牧兽医研究所 一种用于杀灭沙门氏菌的复合酶系及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994390A (en) * 1989-03-13 1991-02-19 Nalco Chemical Company Enzyme blend containing cellulase to control industrial slime
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
US5445957A (en) * 1994-02-10 1995-08-29 Triarco Industries, Inc. Enzyme food supplement composition containing beta-fructofuranosidase, cellulase and hemicellulase
GB9409336D0 (en) * 1994-05-10 1994-06-29 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis
EP0805856B2 (en) * 1995-01-26 2009-04-01 Novozymes A/S Animal feed additives comprising xylanase
WO1996031610A2 (en) 1995-04-07 1996-10-10 Betzdearborn Inc. Exopolysaccharide degrading enzyme and use of the same
US6365208B1 (en) * 1995-06-29 2002-04-02 Mcneil-Ppc, Inc. Stable lactase tablets
KR19990067354A (ko) * 1995-11-06 1999-08-16 한센 핀 베네드, 안네 제헤르 동물 사료 첨가제
US6599714B1 (en) * 1996-03-13 2003-07-29 University Technologies International Inc. Method of growing and analyzing a biofilm
US6100080A (en) * 1996-12-18 2000-08-08 Novo Nordisk A/S Method for enzymatic treatment of biofilm
GB2327345B (en) * 1997-07-18 1999-06-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for controlling bacterial infection
CA2299295C (en) * 1997-08-08 2010-11-30 Aventis Pharma Deutschland Gmbh Substituted tetrahydropyrane derivatives and method for producing same
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
US6830745B1 (en) * 1997-10-16 2004-12-14 Pharmacal Biotechnologies, Llc Compositions for treating biofilm
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
DK1100469T3 (da) * 1998-07-28 2005-04-18 Takeda Pharmaceutical Hurtigt henfaldende fast præparat
JP2000226335A (ja) * 1998-12-04 2000-08-15 Amano Pharmaceut Co Ltd 経口用酵素製剤、酵素含有食材及び酵素製剤の服用方法
US7153503B1 (en) * 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
CA2284103A1 (en) * 1999-09-30 2001-03-30 Edith Bonnelye Estrogen related receptor, err.alpha., a regulator of bone formation
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
IL133851A (en) 1999-12-31 2002-12-01 Smoler Feed Additives And Tech Dietary supplement for animals
US6855548B2 (en) * 2000-02-08 2005-02-15 F. Hoffman-La Roche Ag Use of acid-stable proteases in animal feed
JP2001325067A (ja) 2000-05-17 2001-11-22 Ricoh Co Ltd 筆記情報処理装置と筆記情報処理システム及び情報記録媒体
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
AU2001269939A1 (en) * 2000-06-19 2002-01-02 Novozymes Biotech, Inc. Methods for eliminating the formation of biofilm
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
EP1404307A2 (en) * 2001-04-04 2004-04-07 Edith Bonnelye Estrogen receptor-related receptor alpha (err) agonist for inducing cartilage formation
US20030113742A1 (en) * 2001-04-20 2003-06-19 University Of Iowa Research Foundation Methods and compositions for the modulation of biofilm formation
US20030099626A1 (en) * 2001-11-20 2003-05-29 Health Education Corporation Nutrient absorption enhancing compositions and methods
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
IL162823A0 (en) * 2002-01-03 2005-11-20 Yissum Res Dev Co Edible compositions capable of removing oral biofilm
CN1642496A (zh) 2002-03-26 2005-07-20 拜奥辛尼克休斯公司 细菌生物薄膜的酶破坏
AU2003221809A1 (en) * 2002-04-05 2003-10-27 Novozymes North America, Inc. Improvement of strength and abrasion resistance of durable press finished cellulosic materials
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
DE10237317B4 (de) * 2002-08-15 2010-04-08 3M Espe Ag Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20050079594A1 (en) * 2002-10-31 2005-04-14 Karine Marion Method of removing a biofilm
EP1585809A4 (en) * 2002-12-20 2006-08-02 Univ New Jersey Med COMPOSITIONS AND METHODS FOR ENZYME SEPARATION OF BACTERIA AND PIL-BIOFILMS
WO2004066945A2 (en) * 2003-01-24 2004-08-12 Diversa Corporation Enzymes and the nucleic acids encoding them and methods for making and using them
US6692726B1 (en) * 2003-02-11 2004-02-17 Colgate Palmolive Company Enzyme containing oral composition having enhanced stability
US7067124B2 (en) * 2003-03-28 2006-06-27 National Enzyme Company Protease composition and method for treating a digestive disorder
US7700544B2 (en) * 2003-06-12 2010-04-20 Queens's University At Kingston Compositions and methods for treating atherosclerosis
JP2007500697A (ja) * 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
WO2005027832A2 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Edta containing compositions and uses thereof
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
EP1796656A2 (en) * 2004-09-17 2007-06-20 Oystershell NV Composition for inhibiting or preventing the formation of a biofilm
US9023323B2 (en) * 2004-12-16 2015-05-05 Colgate-Palmolive Company Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces
US20060140881A1 (en) * 2004-12-22 2006-06-29 Guofeng Xu Oral care compositions containing flavonoids and flavans
US20070020237A1 (en) * 2005-06-01 2007-01-25 Biotech Institute For International Innovation, Inc. Glucose inducible insulin expression and methods of treating diabetes
US8512724B2 (en) * 2005-06-10 2013-08-20 The Board Of Regents Of The University Of Texas System Antiseptic compositions
DE102005049649A1 (de) * 2005-10-18 2007-04-19 Pro Natura Gesellschaft für gesunde Ernährung mbH Zusammensetzung zur Linderung von Beschwerden des Magen-Darm-Trakts
US20090175842A1 (en) * 2006-07-11 2009-07-09 Chandrakant Laxminarayan Rathi Dietary anti-bacterial compositions
US20080019956A1 (en) * 2006-07-24 2008-01-24 Manoj Kumar Enzymatic prevention and control of biofilm
EP2504025A4 (en) * 2009-11-23 2013-05-01 Stephen F Olmstead COMPOSITIONS AND METHODS USING SERRATIA PEPTIDASE FOR INHIBITING AND TREATING BIOFILMS ASSOCIATED WITH PARTICULAR SUFFERING

Also Published As

Publication number Publication date
EP2254591A2 (en) 2010-12-01
US20180258460A1 (en) 2018-09-13
PL2254591T3 (pl) 2018-01-31
JP2011511809A (ja) 2011-04-14
JP6047273B2 (ja) 2016-12-21
JP6244291B2 (ja) 2017-12-06
EP2254591A4 (en) 2012-09-12
WO2009100456A2 (en) 2009-08-13
US11078516B2 (en) 2021-08-03
NO2254591T3 (da) 2017-12-23
PT2254591T (pt) 2017-11-10
US20210332409A1 (en) 2021-10-28
ES2645062T3 (es) 2017-12-04
US20090202516A1 (en) 2009-08-13
CA2715266A1 (en) 2009-08-13
WO2009100456A3 (en) 2009-12-03
EP2254591B1 (en) 2017-07-26
JP2015110559A (ja) 2015-06-18

Similar Documents

Publication Publication Date Title
DK2254591T3 (da) Inhibering eller behandling af gastrointestinal biofilm
NL300938I2 (nl) Niraparib tosylaat of niraparib tosylaat monohydraat
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
DK2350116T3 (da) Behandling af biofilm
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
DK2300560T3 (da) Termisk behandling af biomasse
DK2395991T3 (da) Anvendelse af eicosapentaensyreethylester til behandling af hypertriglyceridæmi
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK3208269T3 (da) Inhibitorer af c-fms-kinase
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
DK2254598T3 (da) Kombination af alfa 7-nikotinagonister og antipsykotika
DK2349310T3 (da) Polypeptid til behandling eller forebyggelse af adhæsioner
FI20075600A0 (fi) Komponentin eliniän määritys
DK2403512T3 (da) Sammensætninger af polymer myrcen
IT1391986B1 (it) Ciabatta di tipo perfezionato
DK3284820T3 (da) Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger
DK2459129T3 (da) Forbedringer af karstøtteanordninger
DK2252317T3 (da) Behandling af makuladegeneration
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3